Premium
SAFETY AND RESPONSE AFTER 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL)
Author(s) -
Metzger M.,
MauzKörholz C.,
Flerlage J.,
Bartelt J.,
Billett A.,
Choi J.K.,
Ehrhardt M.,
Georgi T.,
Hasenclever D.,
Wang F.,
Zhang H.,
Kaste S.C.,
Kluge R.,
Körholz D.,
Kurch L.,
Link M.,
Stoevesandt D.,
Hudson M.M.,
Krasin M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.25_2629
Subject(s) - medicine , vincristine , regimen , brentuximab vedotin , adverse effect , anaplastic large cell lymphoma , oncology , gastroenterology , lymphoma , nuclear medicine , chemotherapy , hodgkin lymphoma , cyclophosphamide